Boehringer Ingelheim selects ChemAxon’s chemistry software

Friday, February 15, 2013 12:11 PM

Boehringer Ingelheim has chosen ChemAxon, a provider of chemistry software solutions and consulting services for life science research, as its provider for a chemistry software platform for multiple applications across R&D, supporting in-house activities and work with external collaboration partners.

ChemAxon technology will be used to store, search, calculate and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate. Boehringer Ingelheim chose ChemAxon after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap.

"The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems,” said Alex Drijver, CEO of ChemAxon.

With a client list that includes all of the top 15 global pharma companies, ChemAxon continues to experience significant growth year on year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs